07.10.2015 | press release, Aktuell

The webcast, part of the BioPharma Dealmakers series, is scheduled for 11:00 am EDT on October 14. Webcast registration.

The webcast will explore some of the technologies and companies driving this rapidly developing field of regenerative medicine. Participants will learn about new approaches that have been developed to:

  • Generate autologous cartilage cells for transplantation.
  • Use pluripotent embryonic stem cell-derived oligodendrocyte progenitor cells to treat spinal cord injuries.
  • Enlist mAbs to slow or reverse senescence.
  • Use 3D bioprinting to create tissues for use in drug discovery and medical research.


The webcast will include a round table discussion and a Q&A session to enable participants to contribute their own thoughts on this highly innovative area of regenerative medicine.

Dr. Jeske Smink has extensive experience in the preclinical development of cell therapeutics, specifically in quality aspects of cartilage cell transplants. Other webcast participants include:

  • Dr. Jane S. Lebkowski, Ph.D. is the President of R&D and Chief Scientific Officer of Asterias Biotherapeutics.
  • Dr. Lewis Gruber is CEO and Chief Scientific Officer of SIWA Corporation.
  • Dr. Sharon Collins Presnell is the CTO at Organovo, where she leads their R&D group.
  • Moderator: Gaspar Taroncher-Oldenburg, Ph.D. Dr. Taroncher-Oldenburg is an independent consultant and former managing editor of SciBX: Science-Business eXchange for Nature Publishing Group and the former scientific editor at Nature Biotechnology.

About the Webcast

BioPharma Dealmakers webcasts are dedicated to small and large companies looking for commercial partnerships. Read the quarterly BioPharma Dealmakers supplement in Nature Biotechnology and Nature Reviews Drug Discovery.

About co.don ® AG: The biopharmaceutical company based near Berlin is one of the leading specialists worldwide in cell cultivation for the regenerative treatment of articular cartilage defects and spinal disc defects. The company's pharmaceutical products are used to treat cartilage damage. Left untreated, cartilage defects can often result in joint replacement surgery. Orthopaedic, accident and neuro-surgeons are increasingly applying these regenerative therapy methods. co.don® AG is listed on the Frankfurt Stock Exchange (ISIN: DE000A1K0227).

Executive Board: Dirk Hessel (CEO) and Vilma Methner (COO, CSO).

More information is available www.codon.de

Contact:

Matthias Meißner, M.A. webinar@codon.de

Corporate Communications / IR / PR pr@codon.de

+49 +49 3328 43460

Fax: +49 03328 434643

distributed by